Symptoms and General Pathology

All Conditions

Nutritional and Metabolic Diseases

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Syndrome

Obesity

Polycystic Ovary Syndrome

Insulin Resistance

Hyperinsulinism

Metabolic Diseases

Glucose Metabolism Disorders

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Other Dietary Supplements

Testosterone

Dehydroepiandrosterone

DHEA (Dehydroepiandrosterone)

30 healthy women with BMI \< 30 between 18 and 35 years old

2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score \>8 and/ or hyperandrogenemia defining the testosterone level \> 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level \> 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume \>10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI \< 30 between age of 18 and 35.

Obese group are the women with BMI \> 30 between age of 18 and 35.

hepassocin levels in polycystic ovary syndrome

hepassocin

fatma ketenci gencer

sibel bektas

The investigators aimed to investigate hepassocin levels in patients with polycystic ovary syndrome (PCOS). There are 3 groups aged between 18 and 35 years as non-obese healthy women, non-obese women with PCOS, and obese women (BMI\>30) with PCOS.

Hepassocin, also known as Fibrinogen-like-protein or hepatocyte-derived fibrinogen-related protein 1, is a new marker for obesity and insulin resistance. In hepatic injury, it protects liver cells and promotes regeneration. High levels of hepassocin was shown to be independently associated with HOMA-IR and diabetes. Since insulin resistance is known to be seen in patients with PCOS, it may be expected that hepassocin levels may be higher in this group of patients.

Early follicular phase day 3 in case of menstruating and random day for amenorrheic patients was chosen for blood sampling after 8 hour of fasting. The blood samples were obtained from the antecubital vein via a vacutainer. Process of samples was achieved within maximum 1 hour and serum sample was stored in -80 for hepassocin work-up after 5 minutes of centrifuge.

Hepassocin Levels in Patients With Polycystic Ovary Syndrome

hepassocin levels should be increased in polycyctic ovary syndrome due to its relation with insulin resistance.

Fatma ketenci gencer

principal invastigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Hepassocin Levels in Patients With Polycystic Ovary Syndrome	NCT04369248	Hepassocin (Hep... Polycystic Ovar... Obesity Insulin Resista...	hepassocin	18 Years - 35 Years	Gaziosmanpasa Research and Education Hospital
Hepassocin Levels in Patients With Polycystic Ovary Syndrome	NCT04369248	Hepassocin (Hep... Polycystic Ovar... Obesity Insulin Resista...	hepassocin	18 Years - 35 Years	Gaziosmanpasa Research and Education Hospital

Spots Global Cancer Trial Database for hepassocin

Every month we try and update this database with for hepassocin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for hepassocin

Every month we try and update this database with for hepassocin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for hepassocin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.